Geneva, Switzerland, November 23, 2023 - Addex Therapeutics , a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that.
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Press Release: Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced it had received written notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable cr